Creature Companion February March 2019 | Page 42

Pet Nutrition Sources and chemistry Beta-glucans in the aleurone layer of cereal grains have linear, bended structures. Th eir cellulose-like fragments, generally consisting of three or four of glucose units with β-(1, 4) bonds, are interrupted by a single β-(1, 3) linkage. Beta-glucans from yeast (Saccharomyces cerevisiae) comprise β-(1, 3)-linked glucose residues with small numbers of β-(1, 6)-linked branches. Th e approximate levels of total beta-glucans in cereal grains are as follows: corn, 1.0%; rice, 0.7%; barley, 3.8%; wheat, 0.8%; oat, 3.7% (1-5). Dried spent brewer’s yeast has about 11% total beta-glucans (6-9). Yeast preparations marketed as immune stimulator contain some 60% beta-1,3/1,6- glucans (6, 10). Dry food with 50% of a grain species holds 0.35 to 1.9% cereal beta- glucans. Food with 1% dried brewer’s yeast or a derivative, contains 0.1 or 0.6% yeast beta-glucans. Macronutrient digestibility Beta-glucans are resistant to the dogs’ digestive enzymes, but are degraded by the colonic bacteria. Barley beta-glucans were moderately fermented by dog fecal microfl ora (11, 12). High intakes of beta- glucans may raise ileal digesta viscosity, thereby impairing digestion. In dogs dosed with oat-derived beta-glucans at a rate of 1% of the dry food off ered, apparent digestibility of dry matter was reduced by 4.6 %units, while fecal mass grew larger and loosened up (13). In dogs, apparent digestion of protein in dehulled barley was 3.5 %units lower than that for wheat (14, 15). Replacement of 35% wheat in dry food by barley decreased protein digestibility by 7 %units and made stools more loose and moist. Th e eff ects were partly counteracted by spraying a mixture of beta-glucanase, xylanase and amylase onto the diet (16). Clearly, the diet contrasts in the digestibility trials (14-16) involved more than barley beta-glucans only. 42 Immunomodulatory concept Various intestinal, innate immune cells have so-called pattern recognition receptors (PRRs) that may bind diet-derived beta- glucans, just as they do with beta-1,3-glucans in cell walls of certain pathogenic yeasts, fungi and bacteria. Receptor binding signals phagocytosis and pathogen degradation by the leukocytes of the innate immune system. Leukocytes also release cytokines and antigens that stimulate antibody production by the adaptive immune system. Th e altered cytokine profi le may protect against infl ammation. Dietary beta-glucans act as immunomodulator only if quantity and structure are eff ective on their arrival at the intestinal, innate immune cells. Beta- glucans of higher purity are active, unlike beta-glucans embedded in (partially digested) food ingredients. PPRs are highly specifi c for pure β-(1,3) backbone structures (17). Immune indicators Oral administration of purifi ed beta-glucans from yeast or oyster mushroom enhanced antigen-induced immune responses. Dogs were injected with ovalbumin (10, 18) or vaccinated against rabies plus parvovirus (19-21) and bordetella (22). In- vitro phagocytosis, as index of the innate immune system, was quantifi ed as leukocyte percentages with internalized polystyrene beads. Serum levels of specifi c antibodies against the antigens served as measure of the adaptive immune system. Th e equivalent of 0.08% purifi ed beta- glucans in dry food stimulated phagocytosis by 43% and induced a 3.36-fold increase in specifi c antibodies. Th ese mean eff ects concern 3 to 10 weeks post-antigen injection and four studies (10, 18-22). Infl ammatory diseases In double-blinded, placebo-controlled trials, lasting 8 weeks, dogs with osteoarthritis (n = 23/group) or atopic dermatitis (n = 15 or Creature Companion | February - March 2019 • Vol. XII • Issue 2 • Noida 16) received dry food without or with 0.08% of a purifi ed yeast beta-glucan preparation (23, 24). Beta-glucan treatment improved owner-assessed severity scores of arthritis and atopy by 79 and 63%. In dogs (n = 7) with infl ammatory bowel disease, feeding dry food without or with 0.05% purifi ed yeast beta-glucan for six weeks changed the clinical index (scale 0-18) from 5.8 to 7.1 or 6.0 to 0.9 (25). Reproducibility is unknown for each trial. List of references is available on request from the author ([email protected]) * Dr Anton C Beynen writes this exclusive column on dog and cat nutrition every month. He is affi liated with Vobra Special Petfoods.